SRI 31215
CAS No. 1832686-44-8
SRI 31215( —— )
Catalog No. M20215 CAS No. 1832686-44-8
SRI 31215 a small molecule that acts as a triplex inhibitor of matriptase hepsin and HGFA and mimics the activity of HAI-1/2 endogenous inhibitors of HGF activation with IC50s of 0.69 μM 0.65 μM 0.3 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 79 | In Stock |
|
| 5MG | 132 | In Stock |
|
| 10MG | 205 | In Stock |
|
| 25MG | 413 | In Stock |
|
| 50MG | 617 | In Stock |
|
| 100MG | 879 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSRI 31215
-
NoteResearch use only, not for human use.
-
Brief DescriptionSRI 31215 a small molecule that acts as a triplex inhibitor of matriptase hepsin and HGFA and mimics the activity of HAI-1/2 endogenous inhibitors of HGF activation with IC50s of 0.69 μM 0.65 μM 0.3 μM.
-
DescriptionSRI 31215 a small molecule that acts as a triplex inhibitor of matriptase hepsin and HGFA and mimics the activity of HAI-1/2 endogenous inhibitors of HGF activation with IC50s of 0.69 μM 0.65 μM 0.3 μM
-
In VitroWestern Blot Analysis Cell Line:DU145 cells Concentration:10 μM Incubation Time:30 min Result:Prevented fibroblast-induced MET activation and signaling in tumor cells, but did not prevent MET activation induced by active HGF.Cell Migration Assay Cell Line:DU145 cells Concentration:10 μM Incubation Time:24 h Result:Did not interfere with HGF-induced migration, but inhibited fibroblast-induced migration of DU145 cells.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
RecptorHGFA|matriptase|hepsin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1832686-44-8
-
Formula Weight533.6
-
Molecular FormulaC27H34F3N5O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:Soluble
-
SMILESOC(=O)C(F)(F)F.OC(=O)C(F)(F)F.CC1CN(CC2CCN(Cc3ccccc3)CC2)C(=O)N(C1)c1cccc(c1)C(N)=N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Owusu BY et al. Inhibition of pro-HGF activation by SRI31215 a novel approach to block oncogenic HGF/MET signaling. Oncotarget. 2016 May 17;7(20):29492-506.
molnova catalog
related products
-
AMG-337
AMG-337 is a potent and selective inhibitor of MET with biochemical IC50 of 1 nM; inhibits of HGF-mediated MET phosphorylation in PC3 cells.
-
c-Met inhibitor 1
c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.
-
Terevalefim
Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor.
Cart
sales@molnova.com